OA9 OppAlerts AI Search Visibility & Ranking Factors
oppalerts.com →
Dermatology Groups

Psoriasis Treatment Planner

Knowledge Graph Entities
Dominant · Search Engine Appearances ρ=0.424

AI recommendation signal analysis across 195 domains for the Psoriasis Treatment Planner persona in Dermatology Groups.

Download this report (.xlsx)
195Domains Tracked
Psoriasis Treatment Planner_persona.report
EntityScore
Mayo Clinic
60.0
University of Texas Southwestern Medical Center
60.0
Cleveland Clinic
60.0
Human Resource Management Review
60.0
Temple University Health System
60.0
Entitys rankedn = 25
Want a custom AI visibility audit for Dermatology Groups?

This report tracks how AI models and search engines recommend companies across 100 industries. If you want the same analysis run specifically against your own site and competitors, get in touch.

Get in touch →
About This Report

How to use this page

Persona view: this page is scoped to this persona's queries alone.
Use Case

Check your knowledge-graph footprint

Wikidata is the structured knowledge graph behind Wikipedia, search engines, and many AI systems. If the graph does not know a brand, machines have less to anchor an answer on. See which entities carry this segment's topics and brands, and whether its top domains have an entity at all.

How It's Calculated

Where the numbers come from

We scan every Wikidata entity record (labels, descriptions, property values) for this segment's topic phrases and brand hostnames. Entity records are short structured data, so counts run far smaller than article text. Coverage checks which entities claim each domain as an official website.

Overview

What's on this page

Top-entity charts, the full entity table, and a knowledge-graph coverage check for this segment's most LLM-recommended domains.

Segment Totals

Knowledge graph at a glance

How much of the Wikidata knowledge graph touches Psoriasis Treatment Planner. Entity records are short structured data (labels, descriptions, property values), so these counts run far smaller than Wikipedia article text; what matters is which entities show up, not raw volume.

39K
Entities With Topic Matches
5,771
Entities Mentioning Brands
40K
Topic Phrase Matches
6,162
Brand Mentions
Top Domains

Knowledge graph coverage

Whether a Wikidata entity claims each of this segment's most LLM-recommended domains as its official website. A brand without an entity is invisible to systems that navigate the web through the knowledge graph.

18 of 25 top domains for Psoriasis Treatment Planner have a knowledge-graph entity.

DomainKnowledge Graph EntityWikidata ID
aad.orgAmerican Academy of DermatologyQ4742879
psoriasis.orgNational Psoriasis FoundationQ6975105
mountsinai.orgMount Sinai HospitalQ1476505
mayoclinic.orgMayo ClinicQ1130172
nationalpsoriasis.orgNot in the knowledge graph-
clevelandclinic.orgCleveland ClinicQ4117596
pennmedicine.orgPennsylvania HospitalQ1273145
nyulangone.orgNYU Langone HealthQ6956114
massgeneral.orgMassachusetts General HospitalQ126412
ucsfhealth.orgUCSF Medical CenterQ7864122
hopkinsmedicine.orgJohns Hopkins MedicineQ50363516
mayo.eduMayo School of Health SciencesQ6797552
dermnetnz.orgQ136755151Q136755151
stanfordhealthcare.orgStanford Health Care Tri-ValleyQ130530767
npf.orgNot in the knowledge graph-
aadermatology.comNot in the knowledge graph-
nationalpsoriasisfoundation.orgNot in the knowledge graph-
massgeneralbrigham.orgMass General BrighamQ7140719
uclahealth.orgUCLA Health SystemQ18394900
northwesternmedicine.orgNot in the knowledge graph-
webmd.comWebMDQ3536160
nm.orgNorthwestern Medicine McHenry HospitalQ5059054
mountsinaihealthsystem.orgNot in the knowledge graph-
health.ucdavis.eduUniversity of California Davis Department of Public Health SciencesQ101018506
dermatology.columbia.eduNot in the knowledge graph-
25 domainsAll results shown
Wikidata

Top knowledge-graph entities

The entity records where Psoriasis Treatment Planner's brands and topics appear. Brand Mentions is the more reliable single ranking here; broadly used phrases can surface large unrelated entities in the topic view. Blended merges the two on a log scale (brand mentions weighted higher, 0 to 100). Bars and entity names link to the record; entities with no label show their Wikidata ID. The table follows the selected view.

EntityBlendedBrand MentionsTopic Matches
Mayo Clinic60.040
University of Texas Southwestern Medical Center60.040
Cleveland Clinic60.040
Human Resource Management Review60.040
Temple University Health System60.040
Frontiers in Energy Efficiency60.040
University of Southern California51.730
Q22988351.730
United States National Institutes of Health51.730
Toxicological Sciences51.730
Brain and Language51.730
Virology51.730
Applied Mathematics and Computation51.730
Advances in Virus Research51.730
Polish Music Journal51.730
Advances in Parasitology51.730
Advances in Nutrition51.730
Harvard men's health watch51.730
Harvard women's health watch51.730
Chronic Diseases and Translational Medicine51.730
World Journal of Otorhinolaryngology-Head and Neck Surgery51.730
University of Washington Museology Master of Arts Program51.730
Clinical trial NCT0759738251.730
Clinical trial NCT0758582551.730
Clinical trial NCT0757161651.730
Clinical trial NCT0757162951.730
Clinical trial NCT0761103251.730
Skin Cancer Foundation45.811
Schweiger Dermatology Group (United States)45.811
Journal of psoriasis and psoriatic arthritis45.811
Wave Motion41.020
Ultrasonics Sonochemistry41.020
University of Pennsylvania41.020
Massachusetts General Hospital41.020
Nucleic Acids Research41.020
University of Washington41.020
Clinical Genitourinary Cancer41.020
Journal of Economic Theory41.020
Blood41.020
Tetrahedron Letters41.020
BioScience41.020
Nuclear Physics41.020
Tulane University41.020
Trends in Cell Biology41.020
Intelligence41.020
Journal of Operations Management41.020
Kaiser Permanente41.020
Annals of Botany41.020
Brachytherapy41.020
Mechanisms of Ageing and Development41.020
Trends in Cardiovascular Medicine41.020
Frontiers in Neuroanatomy41.020
Seminars in Cancer Biology41.020
Journal of Crystal Growth41.020
Field Crops Research41.020
Cardiovascular Pathology41.020
Biophysical Journal41.020
Physica C41.020
Computer Communications41.020
Robotics and Autonomous Systems41.020
Marine Micropaleontology41.020
Comptes Rendus. Biologies41.020
Frontiers in Cellular Neuroscience41.020
Mathematical Biosciences41.020
International Journal of Medical Informatics41.020
Postharvest Biology and Technology41.020
Nuclear Physics A41.020
Toxicology and Applied Pharmacology41.020
Advances in Agronomy41.020
Cancer Detection and Prevention41.020
Cancer Radiothérapie41.020
Microelectronic Engineering41.020
Optical Switching and Networking41.020
Journal of Communication Disorders41.020
Biological Journal of the Linnean Society41.020
Agricultural Systems41.020
Applied Catalysis A: General41.020
Applied Clay Science41.020
Frontiers in Pharmacology41.020
International Review of Cytology41.020
International Journal of Obstetric Anesthesia41.020
Frontiers in Psychology41.020
Nuclear Physics B41.020
Annales pharmaceutiques françaises41.020
Coordination Chemistry Reviews41.020
Food Chemistry41.020
Journal of Molecular Structure41.020
Journal of the American Society for Mass Spectrometry41.020
Electrochemistry Communications41.020
Fuel Processing Technology41.020
Advances in Cancer Research41.020
Journal of Fluorine Chemistry41.020
Journal of Nutrition41.020
Journal of Pharmaceutical Sciences41.020
Microporous and Mesoporous Materials41.020
PatientsLikeMe41.020
Progress in Solid State Chemistry41.020
Radiation Physics and Chemistry41.020
Rusk Institute of Rehabilitation Medicine41.020
Vibrational Spectroscopy41.020
Physiology & Behavior41.020
Vacuum41.020
Perelman School of Medicine at the University of Pennsylvania41.020
Computers and Electronics in Agriculture41.020
Advances in Mathematics41.020
American Journal of Preventive Medicine41.020
American Journal of Translational Research41.020
Biomedical Optics Express41.020
Brain Research41.020
British Journal of Dermatology41.020
China Economic Review41.020
ClinicalTrials.gov41.020
Cultural Diversity and Ethnic Minority Psychology41.020
dbSNP41.020
drugs.com41.020
Duke University Health System41.020
Early Childhood Research Quarterly41.020
Experimental Hematology41.020
Geochimica et Cosmochimica Acta41.020
The Journal of Biochemistry41.020
Journal of Memory and Language41.020
Journal of Second Language Writing41.020
Journal of Sound and Vibration41.020
Journal of the Academy of Nutrition and Dietetics41.020
LabCorp41.020
Laboratory Investigation41.020
Learning and Individual Differences41.020
Loyola University Medical Center41.020
Magnetic Resonance Imaging41.020
Museum Management and Curatorship41.020
Nationwide Children's Hospital41.020
Northwell Health41.020
Personality and Individual Differences41.020
Quaternary Research41.020
Western Journal of Medicine41.020
Houston Methodist Hospital41.020
Transplantation Proceedings41.020
Trends in Amplification41.020
Ulster Medical Journal41.020
University of Pittsburgh Medical Center41.020
UpToDate41.020
The AAPS Journal41.020
Finite Elements in Analysis and Design41.020
Linear Algebra and its Applications41.020
Annales de l'Institut Henri Poincare C41.020
Applied Mathematics Letters41.020
Applied Numerical Mathematics41.020
Current Opinion in Genetics & Development41.020
Journal of Fluency Disorders41.020
Nonlinear Analysis41.020
Nuclear Instruments & Methods in Physics Research B41.020
Rice41.020
Seminars in Cell & Developmental Biology41.020
Systems & Control Letters41.020
NeuroToxicology41.020
Differential Geometry and its Applications41.020
Journal of Combinatorial Theory, Series B41.020
Journal of Mathematical Analysis and Applications41.020
Journal of Web Semantics41.020
Pathophysiology41.020
BJOG: an International Journal of Obstetrics and Gynaecology41.020
Archives of Gerontology and Geriatrics41.020
Cryptogamie Bryologie41.020
Advances in Marine Biology41.020
BBA: Molecular Basis of Disease41.020
Global Finance Journal41.020
Advances in Carbohydrate Chemistry and Biochemistry41.020
AAPS PharmSciTech41.020
Brain and Development41.020
Cryptogamie Algologie41.020
Aggression and Violent Behavior41.020
Archives of Clinical Neuropsychology41.020
Pediatric Neurology41.020
General Hospital Psychiatry41.020
Comparative Immunology, Microbiology & Infectious Diseases41.020
International Journal of Mental Health Systems41.020
Advances in Applied Microbiology41.020
Optometry - Journal of the American Optometric Association41.020
I C E S Journal of Marine Science41.020
Journal of Policy Modeling41.020
Best Practice and Research: Clinical Gastroenterology41.020
International Journal of Law and Psychiatry41.020
Prostaglandins and Other Lipid Mediators41.020
Building and Environment41.020
Industrial Marketing Management41.020
Meat Science41.020
Research in Organizational Behavior41.020
Fish and Shellfish Immunology41.020
Journal of Immunological Methods41.020
European Journal of Cardiovascular Nursing41.020
Human Pathology41.020
Comparative Biochemistry and Physiology. Part A: Molecular and Integrative Physiology41.020
Journal of the American Academy of Dermatology41.020
The History of the Family41.020
Journal of Environmental Management41.020
Insight41.020
Business Horizons41.020
Computers in Human Behavior41.020
Government Information Quarterly41.020
Linguistics and Education41.020
Cryptogamie Mycologie41.020
Behaviour Research and Therapy41.020
Advances in Botanical Research41.020
Journal of Urban Health41.020
Comptes Rendus. Géoscience41.020
Policy and Society41.020
Neural Development41.020
Socio-Economic Planning Sciences41.020
Organizational Dynamics41.020
The American Journal of Surgery41.020
Clinical Neurophysiology41.020
Ocean Engineering41.020
International Review of Law and Economics41.020
Nuclear Physics B - Proceedings Supplements41.020
Revue Europeene de Psychologie Appliquee41.020
Computers & Graphics41.020
Journal of African Earth Sciences41.020
Journal of the Society of Laparoendoscopic Surgeons41.020
Annual Reports in Medicinal Chemistry41.020
Comparative Biochemistry and Physiology. Part D: Genomics and Proteomics41.020
European Journal of Mechanics A - Solids41.020
Computers and Composition41.020
Review of Financial Economics41.020
Maturitas41.020
Financial Services Review41.020
Mechanics Research Communications41.020
Journal of Cultural Heritage41.020
Clinical Imaging41.020
Journal of Environmental Sciences41.020
Frontiers in Systems Neuroscience41.020
Journal of Clinical Lipidology41.020
Journal of Orthopaedics, Trauma and Rehabilitation41.020
Ticks and Tick-borne Diseases41.020
The Electricity Journal41.020
Social Science Research41.020
Archives of Cardiovascular Diseases Supplements41.020
Frontiers in Energy Research41.020
UCLA Health System41.020
Q2064174241.020
NewYork-Presbyterian Westchester41.020
Frontiers in Bioengineering and Biotechnology41.020
Oregon Graduate Center41.020
Filtration & Separation41.020
Fundamental and Applied Toxicology41.020
Journal of the Less Common Metals41.020
Scripta Metallurgica41.020
Diseases of the chest41.020
Chemical health & safety American Chemical Society, Division of Chemical Health and Safety41.020
Revista paulista de pediatria : orgão oficial da Sociedade de Pediatria de São Paulo41.020
Behavioral Biology41.020
The Journal of clinical and aesthetic dermatology41.020
Alcohol research : current reviews41.020
Cell Biology International Reports41.020
Dermato-endocrinology41.020
British Heart Journal41.020
The western journal of emergency medicine41.020
Prostate international41.020
Psychiatry41.020
Mycobiology41.020
Clinical neurosurgery41.020
The Lancet Psychiatry41.020
Advances in food research41.020
Science in China. Series B, Chemistry, life sciences & earth sciences41.020
Genetic analysis, techniques and applications41.020
Journal of the American Pharmaceutical Association41.020
The Harvard mental health letter41.020
Journal of epilepsy41.020
Ethology and sociobiology41.020
Clinical microbiology newsletter41.020
Frontiers in Psychiatry41.020
Frontiers in Endocrinology41.020
Frontiers in Plant Science41.020
Journal of Verbal Learning and Verbal Behavior41.020
Paediatrics and Child Health41.020
The Lancet: Diabetes & Endocrinology41.020
Frontiers in Cell and Developmental Biology41.020
Frontiers in Ecology and Evolution41.020
Sexual medicine41.020
Frontiers in physics41.020
Avian Research41.020
Alzheimer's & dementia (Amsterdam, Netherlands)41.020
Sexual medicine reviews41.020
Cell Chemical Biology41.020
Operative neurosurgery (Hagerstown, Md.)41.020
Clinical neurophysiology practice41.020
Information and control41.020
Studies in Logic and the Foundations of Mathematics41.020
Computing systems in engineering : an international journal41.020
Loyola Medicine41.020
Advanced Dermatology & Cosmetic Surgery41.020
Kaiser Foundation Health Plan41.020
Kaiser Permanente Anaheim Medical Center41.020
UPMC Health System41.020
UH Cleveland Medical Center41.020
Baylor Scott & White Health41.020
The Journal of Finance and Data Science41.020
Syosset Hospital41.020
Johns Hopkins Medicine41.020
Journal of Urban Management41.020
Evolution Letters41.020
Journal of Asian Ceramic Societies41.020
Climate Risk Management41.020
Information Processing in Agriculture41.020
Advances in Inorganic Chemistry and Radiochemistry41.020
Fish Physiology41.020
Computer Vision, Graphics, and Image Processing41.020
Advanced Optical Technologies41.020
Network Security41.020
Inorganic and Nuclear Chemistry Letters41.020
Inorganica Chimica Acta Reviews41.020
Information Storage and Retrieval41.020
Biometric Technology Today41.020
Membrane Technology41.020
Filtration Industry Analyst41.020
Fuel Cells Bulletin41.020
Journal of Patient Safety & Infection Control41.020
Pump Industry Analyst41.020
Space Research Today41.020
World Pumps41.020
Biology Methods and Protocols41.020
Current Developments in Nutrition41.020
Christopher R. Conley41.020
Water Security41.020
Electroencephalography and Clinical Neurophysiology - Evoked Potentials41.020
Nuclear Data Sheets Section B41.020
Recherche - Transports - Securite41.020
Corporate Environmental Strategy41.020
Current Paediatrics41.020
Zeolites41.020
Frontiers in Genome Editing41.020
Frontiers in Neurogenesis41.020
Heart Rhythm O241.020
International Strategic Management Review41.020
Systems Engineering - Theory & Practice41.020
The Journal of the American Dental Association (1922)41.020
Frontiers in Conservation Science41.020
University of Pennsylvania Division of Endocrinology, Diabetes and Metabolism41.020
Frontiers in Bioinformatics41.020
Green Synthesis and Catalysis41.020
Artificial Intelligence in the Life Sciences41.020
Frontiers in Health Services41.020
PNAS Nexus41.020
Adverse events in cognitive behavioral therapy and relaxation training for children and adolescents with obsessive-compulsive disorder: A mixed methods study and analysis plan for the TECTO trial41.020
Frontiers in High Performance Computing41.020
psoriasis40.003
Q2686201740.003
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)40.003
Excimer laser therapy for hairline psoriasis: a useful addition to the scalp psoriasis treatment algorithm40.003
308-nm excimer laser in psoriasis vulgaris, scalp psoriasis, and palmoplantar psoriasis.40.003
Topical Treatment of Basal Cell Carcinoma with the Immune Response Modifier Imiquimod40.003
Evidence and Suggested Therapeutic Approach in Psoriasis of Difficult-to-treat Areas: Palmoplantar Psoriasis, Nail Psoriasis, Scalp Psoriasis, and Intertriginous Psoriasis40.003
Safety profiles and efficacy of infliximab therapy in Japanese patients with plaque psoriasis with or without psoriatic arthritis, pustular psoriasis or psoriatic erythroderma: Results from the prospective post-marketing surveillance.40.003
Efficacy and safety of open‐label ixekizumab treatment in Japanese patients with moderate‐to‐severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis40.003
A Higher Score on the Dermatology Life Quality Index, Being on Systemic Treatment and Having a Diagnosis of Psoriatic Arthritis is Associated with Increased Costs in Patients with Plaque Psoriasis40.003
Proposal for long-term protocols after Psoriasis Area and Severity Index clear with initial biologic therapy: Happily ever after with or without biologics in psoriasis therapy.40.003
A Phase 3 Clinical Study of KHK 482740.003
Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis40.003
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment40.003
A Study in Participants With Psoriatic Arthritis Attending Dermatology Clinics40.003
Subject Preference for Scalp Psoriasis Treatment40.003
Per-gram cost of medication is by itself a poor indicator for comparing costs of different psoriasis treatments: a retrospective cohort study of the cost of psoriasis treatment with topical corticosteroids versus topical calcipotriene40.003
A Phase 4 Clinical Study of Brodalumab40.003
Comparative efficacy of topical antipsoriatic treatments, systemic treatment and biologics: is severity assessment beyond Psoriasis Area and Severity Index a necessity?40.003
Generalized pustular psoriasis of pregnancy treated with narrowband UVB and topical steroids40.003
Long‐term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma40.003
Biologic Therapy Utilization in Patients With Moderate to Severe Psoriasis and Psoriatic Arthritis: An Observational Summary of Biologic Therapy Use in a Clinical Setting40.003
Cost-Effectiveness Analysis of Sequential Biologic Therapy with Ixekizumab Versus Secukinumab in the Treatment of Active Psoriatic Arthritis with Concomitant Moderate-to-Severe Psoriasis in the UK40.003
Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis40.003
Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review40.003
Correlation of Physician-Assessed Psoriasis Area and Severity Index Scores With Patient-Reported Psoriasis Symptoms and Signs Diary Scores Among Patients With Moderate-to-Severe Psoriasis: Results From VOYAGE 1 and VOYAGE 2 Studies40.003
chloracne31.702
rosacea31.702
skin disease31.702
La Roche-Posay31.702
Mohs surgery31.702
palmoplantar psoriasis31.702
No7 product line31.702
American College of Mohs Surgery31.702
Topical treatments for scalp psoriasis31.702
Topical treatments for chronic plaque psoriasis31.702
Topical treatments for scalp psoriasis31.702
Topical treatments for chronic plaque psoriasis31.702
Topical treatments for chronic plaque psoriasis31.702
Atherosclerosis in psoriatic disease: latest evidence and clinical implications31.702
New and emerging biologic therapies for moderate‐to‐severe plaque psoriasis: mechanistic rationales and recent clinical data forIL‐17 andIL‐23 inhibitors31.702
Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis31.702
Systemic Treatment Approaches in her2-Negative Advanced Breast Cancer—Guidance on the Guidelines31.702
Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis31.702
A Clinical Review of Laser and Light Therapy for Nail Psoriasis and Onychomycosis31.702
Mutations in IL36RN/IL1F5 are associated with the severe episodic inflammatory skin disease known as generalized pustular psoriasis.31.702
Factors affecting prescription of ultra-high potency topical corticosteroids in skin disease: an analysis of US national practice data.31.702
Treatment of inverse psoriasis with the 308 nm excimer laser31.702
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry.31.702
Single Blinded Left-to-Right Comparison Study of Excimer Laser Versus Pulsed Dye Laser for the Treatment of Nail Psoriasis31.702
A 308-nm excimer laser for the treatment of scalp psoriasis31.702
Guidelines for the management of squamous cell carcinoma in organ transplant recipients31.702
308-nm excimer laser for the treatment of scalp psoriasis31.702
The effectiveness of PUVA treatment in severe psoriasis is significantly increased by additional UV 308-nm excimer laser sessions31.702
Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study31.702
Pilot evaluation of supra-erythemogenic phototherapy with excimer laser in the treatment of patients with moderate to severe plaque psoriasis31.702
Benefits of using a hydroquinone/tretinoin skin care system in patients undergoing intense pulsed light therapy for photorejuvenation: a placebo-controlled study31.702
Topical treatments for chronic plaque psoriasis.31.702
Vitiligo Therapy in Children: A Case for Considering Excimer Laser Treatment31.702
The cost effectiveness of biologic therapy for the treatment of chronic plaque psoriasis in real practice settings in Italy.31.702
Dermatology in Ghana: a retrospective review of skin disease at the Korle Bu Teaching Hospital Dermatology Clinic31.702
Efficacy and tolerability of proactive treatment with topical corticosteroids and calcineurin inhibitors for atopic eczema: systematic review and meta-analysis of randomized controlled trials31.702
Efficacy and safety of secukinumab in chronic plaque psoriasis and psoriatic arthritis therapy31.702
308-nm Excimer laser treatment of palmoplantar psoriasis31.702
A simple intervention to reinforce awareness of tanning bed use and skin cancer in non‐medical skin care professionals in Southern California31.702
Knowledge, understanding, and use of preventive strategies against nonmelanoma skin cancer in healthy and immunosuppressed individuals undergoing Mohs surgery31.702
Assessment of risk of psoriatic arthritis in patients with plaque psoriasis: a systematic review of the literature31.702
Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis.31.702
Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis31.702
Topical treatment of vulvar lichen sclerosus with calcineurin inhibitors31.702
Systemic Therapy for Metastatic Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in US Medical Oncology Practice31.702
Atopic Dermatitis: Skin-Directed Management31.702
Skin Cancer Epidemiology, Detection, and Management31.702
The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis31.702
Psoriasis beyond the skin: an expert group consensus on the management of psoriatic arthritis and common co‐morbidities in patients with moderate‐to‐severe psoriasis31.702
Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation31.702
Differentiation between osteoarthritis and psoriatic arthritis: implications for pathogenesis and treatment in the biologic therapy era31.702
Relapse rate and long-term management of plaque psoriasis after treatment with photochemotherapy and dithranol31.702
Ostraceous and inverse psoriasis with psoriatic arthritis as the presenting features of advanced HIV infection31.702
Supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis: Interim results of an open label pilot study31.702
Management of moderate to severe plaque psoriasis with biologic therapy31.702
Pustular psoriasis with adrenal suppression following topical corticosteroids31.702
Evaluation and management of psoriatic arthritis: the role of biologic therapy31.702
Novel treatment of nail psoriasis using the intense pulsed light: a one-year follow-up study31.702
Development of the facial skin care index: a health-related outcomes index for skin cancer patients31.702
Characterization of nonmelanoma skin cancer for light therapy using spatial frequency domain imaging31.702
An open label pilot study of supraerythemogenic excimer laser in combination with clobetasol spray and calcitriol ointment for the treatment of generalized plaque psoriasis31.702
Combination treatment with excimer laser and narrowband UVB light in vitiligo patients.31.702
Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review31.702
Incorporation of Electronic Brachytherapy for Skin Cancer into a Community Dermatology Practice31.702
Erythrodermic Psoriasis Treated with Golimumab: A Case Report31.702
Topical treatment strategies for non-melanoma skin cancer and precursor lesions31.702
Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis31.702
Treatment patterns and costs for anti-TNFα biologic therapy in patients with psoriatic arthritis31.702
Etanercept: a review of its use in the management of plaque psoriasis and psoriatic arthritis31.702
Patient satisfaction with psoriasis therapies: an update and introduction to biologic therapy31.702
Use of a validated screening tool for psoriatic arthritis in dermatology clinics31.702
Otezla (Apremilast), an Oral PDE-4 Inhibitor, Receives FDA Approval for the Treatment of Patients with Active Psoriatic Arthritis and Plaque Psoriasis31.702
Spotlight on etanercept in plaque psoriasis and psoriatic arthritis31.702
Cost-effectiveness of moderate-to-severe psoriasis treatment.31.702
Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey31.702
Long-term management of plaque psoriasis with continuous efalizumab therapy31.702
Providing Guidance for Patients With Moderate-to-Severe Psoriasis Who Are Candidates for Biologic Therapy: Role of the Nurse Practitioner and Physician Assistant31.702
Use of clobetasol in lacquer for plaque psoriasis treatment31.702
Specialist dermatology clinics for organ transplant recipients significantly improve compliance with photoprotection and levels of skin cancer awareness.31.702
Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report31.702
Do topical corticosteroids have a role following excimer laser photorefractive keratectomy?31.702
Sonidegib (Odomzo) for the Systemic Treatment of Adults With Recurrent, Locally Advanced Basal Cell Skin Cancer31.702
Effects of topical corticosteroids on subepithelial haze after excimer laser corneal surgery--objective and quantitative method for evaluating haze31.702
Scalp psoriasis: a review of current topical treatment options.31.702
Skin Cancer in the Crosshairs: Highlights from the Biennial Scientific Retreat of International Transplant Skin Cancer Collaborative and Skin Care in Organ Transplant Recipients Europe31.702
Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry31.702
Economic and Comorbidity Burden Among Moderate‐to‐Severe Psoriasis Patients with Comorbid Psoriatic Arthritis31.702
Topical treatments for scalp psoriasis.31.702
Oral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double‐blind, phase 3 study31.702
New biologics for psoriasis and psoriatic arthritis.31.702
Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption31.702
A study of the safety and efficacy of calcipotriol and betamethasone dipropionate scalp formulation in the long-term management of scalp psoriasis31.702
Evaluation for psoriatic arthritis in dermatology clinics31.702
Could Psoriatic Arthritis Be Easily Diagnosed from Current Suspicious Physical Findings in the Dermatology Clinic?31.702
The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice31.702
Carriers in the Topical Treatment of Skin Disease31.702
Prospective new biologic therapies for psoriasis and psoriatic arthritis31.702
Viral oncogenesis and its role in nonmelanoma skin cancer31.702
A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency.31.702
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology31.702
Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A?systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis31.702
Topical corticosteroids in plaque psoriasis: a systematic review of efficacy and treatment modalities31.702
Topical corticosteroids in plaque psoriasis: a systematic review of risk of adrenal axis suppression and skin atrophy.31.702
Efficacy and safety of combinations of first-line topical treatments in chronic plaque psoriasis: a systematic literature review31.702
Topical treatments for chronic plaque psoriasis of the scalp: a systematic review31.702
Topical treatments for chronic plaque psoriasis: an abridged Cochrane systematic review31.702
When antibiotics can be avoided in skin inflammation and bacterial colonization: a review of topical treatments31.702
Biologic therapy in erythrodermic and pustular psoriasis31.702
The structure, function, and importance of ceramides in skin and their use as therapeutic agents in skin-care products31.702
Biologic Therapy with or Without Topical Treatment in Psoriasis: What Does the Current Evidence Say?31.702
The Role of TNF Inhibitors in Psoriatic Disease31.702
IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease31.702
Patterns of Systemic Treatment for Psoriatic Arthritis in the United States: 2004-2015.31.702
Nail psoriasis as a predictor of the development of psoriatic arthritis31.702
Biologic Therapy for Psoriatic Arthritis31.702
Prophylactic Effect of Oral Minocycline in Combination with Topical Steroid and Skin Care Against Panitumumab-induced Acneiform Rash in Metastatic Colorectal Cancer Patients31.702
The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis31.702
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis31.702
Anti-IL-17 Medications Used in the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review31.702
Screening for Latent Tuberculosis in the Patient With Moderate to Severe Psoriasis Who Is a Candidate for Systemic and/or Biologic Therapy.31.702
Reconstruction of Large Facial Defects after Delayed Mohs Surgery for Skin Cancer31.702
Topical corticosteroids or vitamin D analogues for plaque psoriasis?31.702
Tailor systemic therapy to the patient with severe psoriasis31.702
Treatment of Basal Cell Carcinoma in the Elderly: What Nondermatologists Need to Know31.702
Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis31.702
Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate-to-severe psoriasis in five European countries31.702
Skin disease of penis and male genitalia is linked to atopy and circumcision: caseload in a male genital dermatology clinic.31.702
Systematic review and meta-analysis of randomized clinical trials (RCTs) comparing topical calcineurin inhibitors with topical corticosteroids for atopic dermatitis: A 15-year experience31.702
The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis31.702
Topical treatments for scalp psoriasis: summary of a Cochrane Systematic Review31.702
Initiation, Switching, and Cessation of Psoriasis Treatments Among Patients with Moderate to Severe Psoriasis in the United States31.702
Occupational skin disease among Australian healthcare workers: a retrospective analysis from an occupational dermatology clinic, 1993-2014.31.702
Resistance of Nonmelanoma Skin Cancer to Nonsurgical Treatments. Part I: Topical Treatments31.702
Ixekizumab for treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis31.702
The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis31.702
Second-intention healing of exposed facial-scalp bone after Mohs surgery for skin cancer: review of ninety-one cases.31.702
Short- and Long-Term Management of an Acute Pustular Psoriasis Flare: A Case Report31.702
Actinic damage and skin cancer in albinos in northern Tanzania: findings in 164 patients enrolled in an outreach skin care program31.702
Paradoxical onset of psoriatic arthritis during treatment with biologic agents for plaque psoriasis: a combined dermatology and rheumatology clinical study31.702
Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial31.702
Defining recurrence of nonmelanoma skin cancer after Mohs micrographic surgery: Report of the American College of Mohs Surgery Registry and Outcomes Committee31.702
Thalamic stroke in a young adult with severe psoriasis refractory to adalimumab31.702
Genetic prediction of the effectiveness of biologics for psoriasis treatment31.702
Eradication of MRSA throat carriage - a randomized trial comparing topical treatment with rifampicin-based systemic therapy31.702
Racial differences in skin cancer awareness and surveillance practices at a public hospital dermatology clinic31.702
Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics31.702
Algorithm to select optimal systemic anti‐psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis31.702
Topical treatment for scalp psoriasis: Comparison of patient preference, quality of life and efficacy for non-alcoholic mometasone emulsion versus calcipotriol/betamethasone gel in daily clinical practice31.702
The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice.31.702
Frequency of undiagnosed psoriatic arthritis among psoriasis patients in Australian dermatology practice.31.702
Short‐Term Total Hip Arthroplasty Outcomes in Patients With Psoriatic Arthritis or Psoriatic Skin Disease Compared to Patients With Osteoarthritis31.702
Effect of Psoriatic Arthritis on Treatment Response in Patients With Moderate to Severe Psoriasis31.702
A patient with psoriatic arthritis due to generalized pustular psoriasis (von Zumbusch type)31.702
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.31.702
A Case of Nail Psoriasis Improved by Treatment with Golimumab in a Psoriatic Arthritis Patient31.702
Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series31.702
Costs and Economics of Skin Cancer Management, Mohs Surgery, and Surgical Reconstruction31.702
The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures.31.702
Systemic treatment of severe psoriasis31.702
mTOR signaling cascade in psoriatic disease: Double kinase mtor inhibitor a novel therapeutic target31.702
Psoriatic arthritis in severe psoriasis31.702
Nasal Valve Dysfunction after Mohs Surgery for Skin Cancer of the Nose31.702
Combat dermatology: the prevalence of skin disease in a deployed dermatology clinic in Iraq31.702
No Evidence for Increased Skin Cancer Risk in Koreans with Skin Phototypes III-V Treated with Narrowband UVB Phototherapy31.702
Correlation Between Incisional Biopsy Histological Subtype and a Mohs Surgery Specimen for Nonmelanoma Skin Cancer31.702
Mohs surgery in the treatment of skin cancer.31.702
Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics31.702
Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience31.702
Amelioration of severe psoriasis with psoriatic arthritis for 20 years after allogeneic haematopoietic stem cell transplantation31.702
Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis31.702
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.31.702
Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?31.702
A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis31.702
Occupational skin disease in Finland. An analysis of 10 years of statistics from an occupational dermatology clinic31.702
Onychomycosis in patients of nail psoriasis on biologic therapy: a randomized, prospective open label study comparing Etanercept, Infliximab and Adalimumab31.702
Clinical improvement and satisfaction with biologic therapy in patients with severe plaque psoriasis: results of a European cross-sectional observational study31.702
Treatment of severe psoriasis and psoriatic arthritis with leflunomide31.702
What is the optimal topical treatment for limited plaque psoriasis?31.702
A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.31.702
Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis31.702
Office based dermatological surgery and Mohs surgery: A prospective audit of surgical procedures and complications in a procedural dermatology practice31.702
The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics.31.702
Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease31.702
Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis31.702
Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials31.702
Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): Why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis31.702
Long-term management of scalp psoriasis: perspectives from the international psoriasis council31.702
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial31.702
Topical treatment with diclofenac, calcipotriol (vitamin-D3 analog) and difluoromethylornithine (DFMO) does not prevent nonmelanoma skin cancer in mice31.702
Assessment of the antioxidant/prooxidant status of murine skin following topical treatment with 12-O-tetradecanoylphorbol-13-acetate and throughout the ontogeny of skin cancer. Part II: quantitation of glutathione and glutathione disulfide31.702
Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment31.702
The biological rationale for use of vitamin d analogs in combination with corticosteroids for the topical treatment of plaque psoriasis31.702
Relationship between psoriatic arthritis and moderate-severe psoriasis: analysis of a series of 166 psoriatic arthritis patients selected from a hospital population.31.702
Total skin clearance results in improvements in health-related quality of life and reduced symptom severity among patients with moderate to severe psoriasis31.702
Use of a hydrocolloid dressing in combination with a topical steroid in plaque psoriasis.31.702
Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis31.702
Health economic aspects of psoriasis therapy. Is inpatient topical treatment of plaque-type psoriasis in this age of biologics still appropriate from both medical and economic viewpoints?31.702
Moderate to severe psoriasis treatment challenges through the era of biological drugs31.702
Are we starting to induce skin cancer in order to avoid topical steroids?31.702
Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan31.702
The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review31.702
Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial31.702
Ingestion of topical steroid triggering pustular psoriasis?31.702
Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus31.702
Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression31.702
The evolving role of topical treatments in adjunctive therapy for moderate to severe plaque psoriasis31.702
A randomized, double-blind, vehicle-controlled, bilateral comparison trial of bexarotene gel 1% versus vehicle gel in combination with narrowband UVB phototherapy for moderate to severe psoriasis vulgaris31.702
Topical corticosteroids and corticosteroid sparing therapy in psoriasis management31.702
Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States31.702
Do Malassezia species play a role in exacerbation of scalp psoriasis?31.702
Factors Explaining the Discrepancy Between Physician and Patient Global Assessment of Joint and Skin Disease Activity in Psoriatic Arthritis Patients31.702
Subjective Health Complaints in Individuals with Psoriasis and Psoriatic Arthritis: Associations with the Severity of the Skin Condition and Illness Perceptions - A Cross-Sectional Study31.702
Efalizumab in the treatment of chronic plaque psoriasis: experiences from the largest psoriasis treatment centre in Denmark31.702
Prolonged skin retention of clobetasol propionate by bio-based microemulsions: a potential tool for scalp psoriasis treatment31.702
Clinical evaluation of the effectiveness of Dr Michaels® (also branded as Soratinex®) products in the topical treatment of patients with plaque psoriasis31.702
How Mohs Surgery Transformed Into a First-Line Treatment of Skin Cancer31.702
Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study31.702
Effects of Systemic Treatment with Liarozole on Cutaneous Inflammation, Epidermal Proliferation and Differentiation in Extensive Plaque Psoriasis31.702
Usefulness of dual-energy computed tomography for the evaluation of early-stage psoriatic arthritis only accompanied by nail psoriasis.31.702
The Brigham Scalp Nail Inverse Palmoplantar Psoriasis Composite Index (B-SNIPI): a novel index to measure all non-plaque psoriasis subsets.31.702
A novel, short, and simple screening questionnaire can suggest presence of psoriatic arthritis in psoriasis patients in a dermatology clinic31.702
Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors31.702
Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA): development and validation of a tool for assessment of nail psoriasis outcomes.31.702
Successful ustekinumab treatment of noninfectious uveitis and concomitant severe psoriatic arthritis and plaque psoriasis.31.702
Retrospective audit of patients referred for further treatment following Mohs surgery for non-melanoma skin cancer.31.702
A dramatic response to a single dose of infliximab in a patient with prolonged pustular psoriasis derived from inverse psoriasis31.702
What's up dermatology? A pilot survey of the use of WhatsApp in dermatology practice and case discussion among members of WhatsApp dermatology groups.31.702
Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France.31.702
Skin care and the topical treatment of aging skin31.702
Non-randomized pilot study on the evaluation of the quality of life and psychosocial stress before and after systemic therapy in patients affected by moderate to severe psoriasis.31.702
Early Recognition and Treatment Heralds Optimal Outcomes: the Benefits of Combined Rheumatology-Dermatology Clinics and Integrative Care of Psoriasis and Psoriatic Arthritis Patients31.702
Comorbidity and economic burden among moderate-to-severe psoriasis and/or psoriatic arthritis patients in the US Department of Defense population31.702
Comparative analysis of Lacistema pubescens and dexamethasone on topical treatment of skin inflammation in a chronic disease model and side effects31.702
A cost-effectiveness analysis of calcipotriol plus betamethasone dipropionate aerosol foam versus gel for the topical treatment of plaque psoriasis31.702
Dietary intake of glucono-δ-lactone attenuates skin inflammation and contributes to maintaining skin condition.31.702
PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis31.702
Doubling golimumab doses did not improve skin disease in two obese patients with psoriatic arthritis31.702
Re: "How Mohs Surgery Transformed Into a First-Line Treatment of Skin Cancer".31.702
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal.31.702
Analysis of the Cochrane Review: Topical Treatments for Scalp Psoriasis. Cochrane Database Syst Rev. 2016;2:CD00968731.702
ASSESSMENT OF THE KNOWLEDGE AND ATTITUDES OF NURSES ON THE SKIN CONDITION AND TREATMENT OF DAMAGE31.702
Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.31.702
Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting31.702
Physician Survey Regarding Patient Nonattendance at Follow-up Appointments at a University-Affiliated Medical Dermatology Clinic31.702
The Accuracy of Measurements of Nonmelanoma Skin Cancer Sizes Referred to the Mohs Surgery Clinic31.702
Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland31.702
Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study31.702
Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman31.702
The usefulness of narrowband UVB as a monotherapy for the treatment of chronic plaque psoriasis31.702
Epidemiology of skin disease among children in a referral skin clinic in Singapore31.702
Psoriatic Arthritis and Nail Psoriasis in a Patient with Concomitant Atopic Dermatitis.31.702
The Effect of Psoriatic Arthritis on Ixekizumab Clinical Outcomes in Moderate-to-Severe Psoriasis Patients: A Post Hoc Analysis31.702
Duration of Psoriatic Skin Disease as Risk Factor for Subsequent Onset of Psoriatic Arthritis31.702
A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy31.702
Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics31.702
Limited association between scalp psoriasis and psoriatic arthritis severity and treatment response31.702
Highlighting Interleukin-36 Signalling in Plaque Psoriasis and Pustular Psoriasis31.702
Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment31.702
Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics31.702
Psoriatic Arthritis with Annular Pustular Psoriasis31.702
Comparison of nail lacquer clobetasol efficacy at 0,05%, 1% and 8% in nail psoriasis treatment: prospective, controlled and randomized pilot study31.702
Biologic therapy of psoriatic arthritis.31.702
High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life31.702
Practical experience of biologics for treatment of very severe psoriasis: a retrospective case cohort study of patients with a baseline Psoriasis Area and Severity Index greater than 2031.702
Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab31.702
High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires31.702
Clinical pearl: early diagnosis of nail psoriasis and psoriatic arthritis31.702
Assessment of the antioxidant/prooxidant status of murine skin following topical treatment with 12-O-tetradecanoylphorbol-13-acetate and throughout the ontogeny of skin cancer. Part I: Quantitation of superoxide dismutase, catalase, glutathione pero31.702
THE EFFECT OF BIOLOGIC THERAPY ON THE LIPID PROFILE OF RHEUMATOID ARTHRITIS (RA), PSORIATIC ARTHRITIS (PSA) AND ANKYLOSING SPONDYLITIS (AS) PATIENTS31.702
Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study.31.702
Anti-inflammatory potency testing of topical corticosteroids and calcineurin inhibitors in human volunteers sensitized to diphenylcyclopropenone.31.702
Intractable prurigo nodularis successfully treated with combination therapy with a newly developed excimer laser and topical steroids31.702
Baseline patient characteristics associated with response to biologic therapy in patients with psoriatic arthritis enrolled in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.31.702
A Predictive Model for Primary Closure Lengths in Mohs Surgery Based on Skin Cancer Type, Dimensions, and Location31.702
Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study31.702
Natural history of isolated nail psoriasis and its role as a risk factor for the development of psoriatic arthritis: a single-centre cross-sectional study31.702
A Crohn's disease-associated insertion polymorphism (3020insC) in the NOD2 gene is not associated with psoriasis vulgaris, palmo-plantar pustular psoriasis or guttate psoriasis31.702
Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review31.702
Systemic Treatment of Moderate to Severe Psoriasis in Pediatric Patients in Galicia, Spain: A Descriptive Study31.702
IL-10 Improves Skin Disease and Modulates Endothelial Activation and Leukocyte Effector Function in Patients with Psoriatic Arthritis31.702
Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study31.702
Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study31.702
Network meta-analyses of systemic treatments for psoriasis: a critical appraisal31.702
Adalimumab for the treatment of severe psoriasis and psoriatic arthritis31.702
Recalcitrant annular pustular psoriasis associated with psoriatic arthritis successfully treated with secukinumab31.702
The level of proinflammatory cytokines: interleukins 12, 23, 17 and tumor necrosis factor α in patients with metabolic syndrome accompanying severe psoriasis and psoriatic arthritis31.702
Successful treatment of cutaneous metastatic breast cancer with topical treatments that potentially synergize with systemic therapy: A case series31.702
Narrowband UVB phototherapy31.702
Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies31.702
Increased Frequency of Ig Heavy-Chain HS1,2-A Enhancer *2 Allele in Dermatitis Herpetiformis, Plaque Psoriasis, and Psoriatic Arthritis31.702
A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis31.702
A Study to Explore Efficacy and Safety of ASP015K in Subjects With Moderate to Severe Psoriasis31.702
Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States31.702
Equating Topical Treatment of Severe Psoriasis to Keeping Money in a Mattress31.702
Experience of Non-Melanoma Skin Cancer (NMSC) Mohs Surgery Project31.702
Psoriasis Longitudinal Assessment and Registry (PSOLAR)31.702
Study of the Drug Efalizumab (Raptiva), for Adult Patients With Moderate to Severe Plaque Psoriasis31.702
Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis31.702
A Study to Evaluate Raptiva in Adults With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy31.702
A Multi-Center Study of Short and Long-term Use of Protopic Ointment in Patients With Atopic Dermatitis31.702
Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSONET Registries31.702
Risankizumab Versus Secukinumab for Subjects With Moderate to Severe Plaque Psoriasis31.702
Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain31.702
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis31.702
A Phase 3 Study in Participants With Moderate to Severe Psoriasis31.702
Systematic Review And Meta-Analysis Of Psoriasis Treatments.31.702
Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Psoriasis)31.702
Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy31.702
Psoriatic Arthritis and Psoriasis Treatment Decision Aid31.702
The Safety and Efficacy of a Novel HSP90 Inhibitor (CUDC-305) in the Treatment of Moderate to Severe Psoriasis.31.702
BOSTRIP: Biomarkers of Systemic Treatment Response in Psoriasis31.702
Study to Explore the Effect of Secukinumab, Compared to Placebo, on Fat Tissue and Skin in Plaque Psoriasis Patients31.702
Prevalence of Psoriatic Arthritis in Adults With Psoriasis: An Estimate From Dermatology Practice31.702
Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clini31.702
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)31.702
NB-UVB Phototherapy With and Without Topical LCD Treatment: a Bilateral Pilot Study31.702
ChangE From Any Systemic psoriasiS therapY to Raptiva31.702
A Study to Evaluate Infliximab in Subjects With Moderate-to-Severe Psoriasis Not Responding to Standard or Biologic Therapy (Study P04612)31.702
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data31.702
Ultrasound Enthesitis Response in Psoriatic Arthritis31.702
A Study to Test BI 655130 in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis31.702
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis31.702
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)31.702
Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis31.702
Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis31.702
Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCC31.702
Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis31.702
Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study31.702
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis31.702
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab31.702
Varicella Zoster Vaccine in Patients With Plaque Psoriasis Treated With Biologic Therapy31.702
Apremilast 30mg Bid With Narrowband UVB in the Treatment of Plaque Psoriasis31.702
Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis31.702
A Study of the Early Activity of Ixekizumab (LY2439821) in Moderate-to-Severe Psoriasis31.702
Excimer Laser Phototherapy Outcomes in the Treatment of Psoriasis31.702
Addition of Excimer Laser to Treatment With Acitretin Tablets for Psoriasis of the Palms and Soles31.702
A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis31.702
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis31.702
Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy31.702
Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)31.702
Safety and Efficacy Study of Combination Treatment With Excimer Laser, Clobex Spray, and Vectical Ointment in the Treatment of Psoriasis31.702
AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis31.702
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis31.702
Five-Year Observation of Remicade Treatment for Plaque Psoriasis in Austria (Study P04900)31.702
Open Label Continuation Study in Moderate to Severe Psoriasis31.702
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis31.702
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis31.702
Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment31.702
Multiple-Dose Pharmacokinetics and Potential for Adrenal Suppression Following Treatment With Halobetasol Spray in Patients With Plaque Psoriasis31.702
Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3 (ECZema TRAlokinumab Trial no. 3)31.702
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy31.702
Nail psoriasis in an adult successfully treated with a series of herbal skin care products family a case report31.702
Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies31.702
The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature.31.702
Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative31.702
Management of Psoriasis and Psoriatic Arthritis in a Multidisciplinary Rheumatology/Dermatology Clinic31.702
Study of Secukinumab Compared to Fumaderm® in Adults With Moderate to Severe Psoriasis31.702
Observational Study to Assess Safety and Utility Pattern of Topical Steroids31.702
An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis31.702
308nm Excimer Laser for Treatment of Fingernail Psoriasis31.702
The NOR-SWITCH Study31.702
Does Topical Steroid Treatment Impair the Adrenal Function?31.702
A Safety and Efficacy Study to Evaluate Efalizumab in Combination With UVB for Moderate to Severe Psoriasis31.702
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies31.702
Narrowband UVB Light Therapy to Patients With Dark Skin Types Who Have 10% of Their Body Involved With Psoriasis Vulgaris.31.702
Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-76531.702
Scalp Psoriasis Treatment With a Fiber Optic Comb31.702
LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis31.702
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Mild to Moderate Psoriatic Fingernail/s31.702
Electronic Brachytherapy (eBx)-Mohs Matched Pair - Cohort Study A Multi-Center Retrospective-Prospective Matched Pairs Cohort Study to Assess Long-term Clinical Outcomes of Non-melanoma Skin Cancer Patients Treated With eBx Compared to Non-melan31.702
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis31.702
A Study of KHK4827 (Brodalumab) in Subjects With Moderate to Severe Psoriasis in Korea31.702
A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque Psoriasis31.702
A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)31.702
Buddy Relationships in DermatoloGic Excisions for Skin Cancer31.702
This Study is Being Conducted to Evaluate the Safety, Tolerability, and Efficacy of KD025 Administered Orally for 16 Weeks to Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy or Phototherapy.31.702
This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis31.702
A Study to Evaluate Clear Skin Effect on Quality of Life in Patients With Plaque Psoriasis.31.702
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis Naive to Systemic Treatment31.702
Study to Evaluate the Efficacy and Safety of P-3073 Nail Solution in the Treatment of Nails Affected by Psoriasis31.702
A Study To Evaluate The Efficacy Of Enbrel (REGISTERED) Etanercept Over A Period Of 12 Months In The Routine Treatment Of Patients With Rheumatoid Arthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Or Plaque Psoriasis.31.702
The role of the ambulatory psoriasis treatment center as a cost-effective program for severe psoriasis31.702
DNA-coated carbon adsorbents experimental assessment and results of severe psoriasis treatment31.702
Are new variants of psoriasis therapy (IL-17 inhibitors) safe?31.702
Systemic treatment of severe psoriasis--the role of cyclosporine31.702
Topical steroid therapy in skin disease. A panel discussion31.702
Are topical corticosteroids useful in phototherapy for psoriasis?31.702
[The dermatophytic flora surveyed at the Dermatology Clinic of the Tottori University Hospital from 1981 to 1984--statistic analysis of the patients of various clinical types and a comparative study of the ratios of T. rubrum/T. mentagrophytes at de31.702
Etretinate in severe psoriasis. Results of double-blind study and maintenance therapy in pustular psoriasis31.702
Retinoids in skin cancer and hyperproliferative skin disease31.702
Generalised pustular psoriasis, psoriatic arthritis and nephrotic syndrome associated with systemic amyloidosis31.702
Contact dermatitis due to topical steroids with conceivable cross reactions between topical steroid preparations31.702
Our experience of psoriatic arthritis and psoriasis treatment with methotrexate (author's transl)31.702
Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease31.702
Posttraumatic reflex sympathetic dystrophy anteceding inverse psoriasis and psoriatic arthritis31.702
The effect of topical corticosteroids on refraction and corneal haze following excimer laser treatment of myopia: an update. A prospective, randomised, double-masked study31.702
Skin care and incidence of skin disease in adolescence31.702
Skin care and topical steroids31.702
Juvenile psoriatic arthritis with nail psoriasis in the absence of cutaneous lesions31.702
New psoriasis treatments based upon a deeper understanding of the pathogenesis of psoriasis vulgaris and psoriatic arthritis: a personal appraisal of their use in practice31.702
Double-blind clinical study reveals synergistic action between alpha-hydroxy acid and betamethasone lotions towards topical treatment of scalp psoriasis31.702
Evaluation of the effectiveness of childhood generalized pustular psoriasis treatment in 30 cases31.702
Lack of association of TNF-238A and -308A in Japanese patients with psoriasis vulgaris, psoriatic arthritis and generalized pustular psoriasis31.702
Chronic actinic dermatitis developing during narrowband UVB phototherapy for psoriasis31.702
Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide31.702
Comparison of betamethasone valerate solution with phototherapy (UVB comb) in scalp psoriasis treatment31.702
Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy31.702
Narrowband UVB phototherapy for psoriasis: results with fixed increments by skin type (as opposed to percentage increments)31.702
Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy31.702
Observations on skin cancer in the Zwickau skin clinic31.702
Audit of prescribing practices of topical corticosteroids in outpatient dermatology clinics in north Palestine31.702
Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis31.702
Lack of association between exposure to topical calcineurin inhibitors and skin cancer in adults31.702
Biopsy techniques for skin disease and skin cancer31.702
No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study31.702
Skin cancer in psoriatic arthritis treated with anti-TNF therapy31.702
Etanercept. An effective TNF alpha-antagonist in the treatment of psoriatic arthritis and chronic plaque psoriasis31.702
Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study31.702
Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis31.702
Long-term management after myocardial infarction (Part 1.): Lifestyle modifications31.702
Long-term management of generalized pustular psoriasis with infliximab: case series31.702
Can you tell me more about topical treatments for skin cancer?31.702
Calcineurin inhibitors for the treatment of skin disease: how do they work?31.702
What are the objectives of moderate to severe psoriasis treatment?31.702
Generalized pustular psoriasis following withdrawal of short-term cyclosporin therapy for psoriatic arthritis31.702
Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis31.702
Topical treatments for chronic plaque psoriasis: a summarised Cochrane review31.702
Psoriasis, psoriatic arthritis, or psoriatic disease?31.702
Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index31.702
Coexisting gout, erythrodermic psoriasis and psoriatic arthritis31.702
Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy31.702
Efalizumab: integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis31.702
Pseudoporphyria secondary to narrowband UVB phototherapy for psoriasis31.702
Pustular psoriasis development after initial ustekinumab administration in chronic plaque psoriasis31.702
Topical steroids versus PUVA therapy in moderate plaque psoriasis: A clinical trial along with cost analysis31.702
Prognosis of pretransplant melanoma31.702
Successful treatment with adalimumab in a patient with psoriatic arthritis and generalized pustular psoriasis31.702
High Prevalence of Psoriatic Arthritis in a Cohort of Patients with Psoriasis Seen in a Dermatology Practice31.702
Melanoma in solid organ transplant recipients31.702
15 years of fumaderm: fumaric acid esters for the systemic treatment of moderately severe and severe psoriasis vulgaris31.702
Opinion of Spanish dermatologists regarding the use of biologic therapy in patients with moderate to severe psoriasis31.702
Pustular psoriasis, palmoplantar psoriasis, erythodermal psoriasis and etanercept31.702
Management of atopic dermatitis: nonadherence to topical therapies in treatment of skin disease and the use of calcineurin inhibitors in difficult eczema31.702
The therapeutic benefits of systemic treatment of psoriatic arthritis? The example of golimumab in psoriatic arthritis31.702
Onset of palmoplantar pustular psoriasis while on adalimumab for psoriatic arthritis: a 'class effect' of TNF-alpha antagonists or simply an anti-psoriatic treatment adverse reaction?31.702
Long-term management of erythrodermic psoriasis with anti-TNF agents31.702
Identifying When Therapy for One Skin Disease Is Likely to Exacerbate Another Skin Condition31.702
What can you tell me about Mohs surgery for skin cancer?31.702
Episode of pustular psoriasis after a tuberculin test in a patient with plaque psoriasis on treatment with etanercept31.702
Biologic therapy in psoriatic arthritis mutilans31.702
Facing skin cancer surgery. Mohs surgery may be your best option for nonmelanoma skin cancers31.702
Systemic Therapy for a Genetic Skin Disease31.702
Generalized pustular psoriasis‐like eruptions induced after the first use of adalimumab in the treatment of psoriatic arthritis31.702
Recognizing psoriatic arthritis in the dermatology clinic31.702
Severe psoriasis with positive tuberculosis test and treatment with biologic therapy: a case report31.702
A pilot study on the Psoriasis Area and Severity Index (PASI) for small areas: Presentation and implications of the Low PASI score31.702
Balance of Treg versus T-effector cells during systemic treatment with adalimumab and topical treatment with calcipotriol-betamethasone dipropionate ointment31.702
Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials31.702
TOPICAL CORTICOSTEROIDS BUT NOT CALCINEURIN INHIBITORS INDUCED ATROPHY AFTER FOUR WEEKS31.702
Systemic Treatment Preoperatively vs Postoperatively in HER2 Positive Early Breast Cancer31.702
Skin disease effects the bones. Nail involvement suggests psoriatic arthritis31.702
Broad-band UVB versus paint PUVA for palmoplantar psoriasis treatment31.702
Systemic Therapy for Colorectal Cancer: Patterns of Chemotherapy and Biologic Therapy Use in Nationally Representative US Claims Database31.702
Very low-calorie ketogenic diet may allow restoring response to systemic therapy in relapsing plaque psoriasis31.702
Skin cancer screening campaigns in a Bucharest Dermatology Clinic31.702
Association with Genetic Variants in the IL-23 and NF-κB Pathways Discriminates between Mild and Severe Psoriasis Skin Disease31.702
Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice31.702
Topical Treatment of Onychomycosis as a Realistic Option to Systemic Therapy31.702
Treatment Patterns and Health Care Costs for Patients With Psoriatic Arthritis on Biologic Therapy: A Retrospective Cohort Study31.702
Combination Therapy of Infliximab and Granulocyte/Monocyte Adsorption Apheresis for Refractory Pustular Psoriasis with Psoriatic Arthritis31.702
Iatrogenic Cushing's Syndrome Due to Overuse of Topical Steroid in the Diaper Area31.702
Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis31.702
Successful Secukinumab treatment of generalized pustular psoriasis and erythrodermic psoriasis31.702
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psorias31.702
The comparative immunogenicity of biologic therapy and its clinical relevance in psoriatic arthritis: a systematic review of the literature31.702
Efficacy and safety of secukinumab in treating moderate to severe plaque psoriasis in two real-world Canadian dermatology clinics: a multicenter retrospective study31.702
Appropriate use criteria for basal cell carcinoma Mohs surgery at a single center in the face of high-burden skin cancer: a retrospective cohort study31.702
Syphilis screening before initiation of immunosuppressive and biologic therapy for psoriasis and psoriatic arthritis31.702
Nail Psoriasis Treated With Certolizumab Pegol in Patients With Psoriatic Arthritis: Preliminary Observation31.702
Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK31.702
18F-fluorodeoxyglucose positron emission tomography-based evaluation of systemic and vascular inflammation and assessment of the effect of systemic treatment on inflammation in patients with moderate-to-severe psoriasis: A randomized placebo-control31.702
Efficacy assessment of UVA1 and narrowband UVB for treatment of scalp psoriasis31.702
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants31.702
Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the U.S. Department of Defense Population31.702
Cushing's Syndrome Induced by High-Potency Topical Corticosteroids in Two Children with Palmoplantar Psoriasis Taking Acitretin31.702
Use of antidepressants and benzodiazepine-related hypnotics before and after initiation of TNF-α inhibitors or non-biological systemic treatment in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis31.702
Evaluation of adalimumab biosimilar in treatment of psoriatic arthritis with concomitant moderate to severe chronic plaque psoriasis: An open-labeled, prospective, pilot case series31.702
Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review31.702
Open-label study assessing the efficacy and tolerability of topical skin care and sun protection alone and in combination with intense pulsed light therapy31.702
Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and N31.702
Microemulsion co-delivering vitamin A and vitamin E as a new platform for topical treatment of acute skin inflammation31.702
Recent Advances in Evaluating Impact of Biologic Therapy for Moderate-Severe Psoriasis on Cardiovascular Events and Atherosclerotic Plaque Formation31.702
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential [Corrigendum]31.702
Skin cancer in transplant recipients: Scientific retreat of the international immunosuppression and transplant skin cancer collaborative and skin care in organ transplant patients-Europe31.702
How to choose between IL-17 inhibitors and IL-23 inhibitors for psoriasis31.702
Successful management of infliximab-induced generalized pustular psoriasis without therapy discontinuation in a patient with psoriatic arthritis31.702
Baseline characteristics of patients with moderate-to-severe psoriasis according to previous systemic treatment exposure: The PROSE study population31.702
Urinary detection of corticosteroid in topical treatment of skin disease by 19F MRS31.702
Skin inflammation associated with arthritis, synovitis and enthesitis. Part 1: psoriatic arthritis, SAPHO syndrome, Still's disease, Behçet's disease31.702
Dual biologic therapy for recalcitrant psoriasis and psoriatic arthritis31.702
Cardiovascular risk factors in psoriatic disease: psoriasis versus psoriatic arthritis31.702
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis31.702
Psoriatic Arthritis, Psoriatic Disease, or Psoriatic Syndrome?31.702
Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS)31.702
Defining drug-free remission of skin disease in patients with plaque psoriasis31.702
Topical treatments for skin cancer31.702
Impact of Having Family History of Psoriasis or Psoriatic Arthritis on Psoriatic Disease31.702
Adverse events with IL-17 and IL-23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta-analysis of phase III studies31.702
Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis31.702
Racial Differences in Perceptions of Psoriasis Therapies: Implications for Racial Disparities in Psoriasis Treatment31.702
IL-23 inhibitors for moderate-to-severe psoriasis31.702
COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution31.702
[Topical Treatment of Pruritic Skin Disease and the Role of Community Pharmacists]31.702
Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease31.702
Treatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose Protocol31.702
Gene Variant in the NF-κB Pathway Inhibitor NFKBIA Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease31.702
Delphi-based recommendations for the management of cardiovascular comorbidities in patients with psoriatic arthritis and moderate-to-severe psoriasis31.702
Reply to "COVID-19, syphilis and biologic therapies for psoriasis and psoriatic arthritis: A word of caution"31.702
Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study31.702
Use of secukinumab in a pediatric patient leads to significant improvement in nail psoriasis and psoriatic arthritis31.702
A successful topical treatment for cutaneous inflammatory diseases:an additional or alternative therapy to topical steroids31.702
The 308-nm excimer laser treatment does not increase the risk of skin cancer in patients with vitiligo: A population-based retrospective cohort study31.702
Updates on the Systemic Treatment of Advanced Non-melanoma Skin Cancer31.702
Sustainability and switching of biologics for psoriasis and psoriatic arthritis at Fukuoka University Psoriasis Registry31.702
Representation of older adults in randomized controlled trials on systemic treatment in plaque psoriasis: A systematic review31.702
A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment31.702
A systematic review of herpes zoster incidence and consensus recommendations on vaccination in adult patients on systemic therapy for psoriasis or psoriatic arthritis: From the Medical Board of the National Psoriasis Foundation31.702
Oxymatrine may represent an additional therapeutic tool in severe plaque psoriasis management31.702
Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses31.702
Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis31.702
The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: A systematic review and meta-analysis31.702
Paradoxical Pustular Psoriasis in a Patient With Psoriatic Arthritis on Secukinumab Treatment31.702
Emerging treatment options for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis: evaluating bimekizumab and its therapeutic potential31.702
Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor PF-06700841 Reveal Reduction of Skin Inflammation in Plaque Psoriasis31.702
Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis31.702
Skin inflammation associated with arthritis, synovitis and enthesitis. Part 1: psoriatic arthritis, SAPHO syndrome, Still's disease, Behçet's disease31.702
Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease31.702
Real world data from the use of secukinumab in the treatment of moderate-to-severe psoriasis, including scalp and palmoplantar psoriasis: A 104-week clinical study31.702
Evolution of topical steroids consumption before and after initiation of systemic treatment in psoriasis: epidemiologic study in a real-world analysis of the French national health insurance database31.702
Efficacy of Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis by Baseline Demographics, Disease Characteristics and Prior Biologic Therapy: An Integrated Analysis of the Phase III UltIMMa-1 and UltIMMa-2 Studies31.702
DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults31.702
Investigation of Psoriasis Susceptibility Loci in Psoriatic Arthritis and a Generalized Pustular Psoriasis Cohort31.702
Correction: Relapse rate and long-term management of plaque psoriasis after treatment with photochemotherapy and dithranol31.702
The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience31.702
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA Study31.702
Use of topical corticosteroids and topical calcineurin inhibitors for the treatment of atopic dermatitis in thin and sensitive skin areas31.702
An Analysis of Biopsies for Suspected Skin Cancer at a Tertiary Care Dermatology Clinic in the Western Cape Province of South Africa31.702
Mohs Surgery versus Standard Local Excision for Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma Skin Cancer31.702
Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)31.702
Radiotherapy and Systemic Treatment for Non-melanoma Skin Cancer in the COVID-19 Pandemic31.702
TNF-α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis31.702
Study to Evaluate the Efficacy of Enbrel as a Biological Treatment in Moderate to Severe Plaque Psoriasis Patients31.702
Clinical Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy31.702
Narrowband UVB treatment increases serum 25-hydroxyvitamin D levels in patients with chronic plaque psoriasis31.702
A case of nail psoriasis-associated psoriatic arthritis successfully treated with adalimumab31.702
Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient31.702
A review of neurologic complications of biologic therapy in plaque psoriasis31.702
Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis31.702
Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results31.702
Clinical Review Report: Risankizumab (Skyrizi): (AbbVie): Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy31.702
Mohs Surgery for the Treatment of Skin Cancer: A Review of Guidelines31.702
Pharmacoeconomic Review Report: Risankizumab (Skyrizi): (AbbVie): Indication: For the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy31.702
Patient Group Input Submissions: Ixekizumab (Taltz) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy31.702
CADTH Canadian Drug Expert Committee Recommendation: Guselkumab (Tremfya — Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy31.702
Pharmacoeconomic Review Report: Guselkumab (Tremfya): (Janssen Inc.): Indication: For the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy31.702
Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials31.702
Excimer laser for psoriasis treatment: A case report and short review31.702
Organization of biologic therapy during the COVID-19 pandemic based on example of Dermatology Clinic Centre of Postgraduate Medical Education in Warsaw31.702
Systemic treatment of psoriasis and psoriatic arthritis in the United States: a cross-sectional study31.702
[Sun protection, surgery, radiation, topical and systemic therapy : The huge playing field of dermatologists in the fight against epithelial skin cancer]31.702
Cardiovascular risk in patients with plaque psoriasis and psoriatic arthritis without a clinically overt cardiovascular disease: the role of endothelial progenitor cells31.702
Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-2331.702
Topical Calcineurin Inhibitors and Skin Cancer-Another Piece of the Puzzle31.702
Cost-effectiveness analysis of ixekizumab versus secukinumab in patients with psoriatic arthritis and concomitant moderate-to-severe psoriasis in Spain31.702
Spotlight on Topical Long-Term Management of Plaque Psoriasis31.702
An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound31.702
Successful treatment of refractory palmoplantar psoriasis in a psoriatic arthritis patient with the JAK inhibitor tofacitinib31.702
Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis31.702
Nail Psoriasis Does Not Affect Skin Response to Ixekizumab in Patients With Moderate-To-Severe Psoriasis31.702
Destructive and topical treatments of skin lesions in organ transplant recipients and relation to skin cancer31.702
Histological Evaluation of the Relationships Between Distal Interphalangeal Psoriatic Arthritis and Nail Psoriasis: Correlations With Anatomical Studies of the Normal Nail Unit and the Main Radiological Data Concerning Distal Interphalangeal Psoriat31.702
CD4+/CD8+ T-Cell Ratio Predictive of Surgical Margins in the Treatment of Nonmelanoma Skin Cancer Treated With Mohs Surgery of Patients Infected With the Human Immunodeficiency Virus31.702
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment31.702
FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric/Adolescents in Moderate to Severe Psoriasis? A Systematic Review31.702
Nail Psoriasis Treatment: Insights into Current Progress and Future Trends31.702
Efficacy of in-class IL-23 inhibitor switching: Risankizumab following Guselkumab failure in moderate-to-severe psoriasis treatment31.702
12-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post-hoc analysis of six randomized trials31.702
Association of Nail Psoriasis With Disease Activity Measures and Impact in Psoriatic Arthritis: Data From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry31.702
Evaluation of Improvement in Skin and Nail Psoriasis in Bio-naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO-VIBRANT Study31.702
The Skin May Clear But the Arthritis Won't Disappear: Focusing on Concomitant and New-Onset Psoriatic Arthritis in a Daily Practice Cohort of Psoriasis Patients on Biologic Therapy31.702
The Effects of Apremilast Therapy on Deployability in Active Duty US Army Soldiers With Plaque Psoriasis and Psoriatic Arthritis31.702
In vitro assessment of triterpenoids NVX-207 and betulinyl-bis-sulfamate as a topical treatment for equine skin cancer31.702
Erratum: Mohs Surgery versus Standard Local Excision for Basal Cell Carcinoma, Squamous Cell Carcinoma, and Melanoma Skin Cancer31.702
Successful secukinumab treatment of erythrodermic psoriasis and psoriatic arthritis concomitant with severe noninfectious uveitis: a case report31.702
Management consensus guideline for hepatocellular carcinoma: 2020 update on surveillance, diagnosis, and systemic treatment by the Taiwan Liver Cancer Association and the Gastroenterological Society of Taiwan31.702
Biopsy Techniques for Skin Disease and Skin Cancer: A New Approach31.702
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitors31.702
Involvement of the cytokine TWEAK in the pathogenesis of psoriasis vulgaris, pustular psoriasis, and erythrodermic psoriasis31.702
Is there any effect of accrued structural damage on disease impact in patients with long-standing psoriatic arthritis undergoing systemic therapy?31.702
Disease burden and quality of life in patients with moderate-to-severe psoriasis stratified according to previous systemic treatment exposure31.702
Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations31.702
Profiling Blood Serum Extracellular Vesicles in Plaque Psoriasis and Psoriatic Arthritis Patients Reveals Potential Disease Biomarkers31.702
Biologic Initiation Rate in Systemic-Naïve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database31.702
Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic Dermatitis31.702
A Worldwide Survey on the Understanding of Psoriatic Disease Among Patients With Psoriasis and Psoriatic Arthritis31.702
A Phase 2 Study of Jaktinib in Participants With Moderate to Severe Psoriasis31.702
Comparison Between Systemic Steroids, Topical Steroids, or Calcineurin Inhibitors With Mini Punch Grafting in Treatment of Stable Non-segmental Vitiligo31.702
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy31.702
2 Years Prospective Study to Collect Real-life Data on the Retention, Quality of Life, Effectiveness and Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and31.702
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP31.702
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis31.702
P78: Secukinumab treatment results in sustained improvement in absolute Psoriasis Area and Severity Index and Dermatological Life Quality Index in biologic‐naïve and biologic‐experienced patients with moderate‐to‐severe plaque psoriasis: analysis of31.702
Bounded integer model-based analysis of psoriasis area and severity index in patients with moderate-to-severe plaque psoriasis receiving BI 73035731.702
WATER'S EDGE DERMATOLOGY31.702
LB1107 Enhancing cosmesis while achieving stellar cure rates for early stage non-melanoma skin cancer in the outpatient dermatology clinic using a novel non-invasive modality31.702
P107 Gastrointestinal symptoms in US patients with moderate-severe psoriasis and psoriatic arthritis31.702
PBI41 TREATMENT PATTERNS OF BIOLOGICS AND APREMILAST AMONG PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS BY PSORIATIC ARTHRITIS STATUS31.702
PMU17 BUDGET IMPACT OF SECUKINUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS, PSORIATIC ARTHRITIS, AND ANKYLOSING SPONDYLITIS IN MEXICO31.702
Ixekizumab: targeting plaque psoriasis and psoriatic arthritis31.702
Effect of Oral Simvastatin Therapy on Patients with Plaque Psoriasis Treated with Potent Topical Steroid31.702
PMU67 - COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN THE UNITED KINGDOM31.702
IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis31.702
Bimekizumab: the first bispecific biologic agent facing phase III trial program in both plaque psoriasis and psoriatic arthritis31.702
Efficacy of brodalumab in moderate-to-severe plaque psoriasis after failure of previous biologic therapy: A phase 4, multicenter, open-label study31.702
Psychometric Evaluation of the Psoriasis Symptoms Scale in Patients with Moderate to Severe Plaque Psoriasis31.702
Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 4031.702
Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry31.702
395 Nail psoriasis as a predictor of skin response to ixekizumab in patients with moderate-to-severe psoriasis31.702
238 The risk of keratinocyte carcinoma (KC) in psoriasis patients receiving biologic therapy compared to conventional systemic therapy: Results from The British Association of Dermatologists Biologic Interventions Register (BADBIR)31.702
322 Skin cancer risk among adults with atopic dermatitis exposed to topical calcineurin inhibitors31.702
1,000 entitysAll results shown